Literature DB >> 29216843

Evaluation of the visibility of early gastric cancer using linked color imaging and blue laser imaging.

Yoshikazu Yoshifuku1, Yoji Sanomura2, Shiro Oka1, Mio Kurihara1, Takeshi Mizumoto1, Tomohiro Miwata1, Yuji Urabe1, Toru Hiyama3, Shinji Tanaka4, Kazuaki Chayama1.   

Abstract

BACKGROUND: Blue laser imaging (BLI) and linked color imaging (LCI) are the color enhancement features of the LASEREO endoscopic system, which provide a narrow band light observation function and expansion and reduction of the color information, respectively.
METHODS: We examined 82 patients with early gastric cancer (EGC) diagnosed between April 2014 and August 2015. Five expert and 5 non-expert endoscopists retrospectively compared images obtained on non-magnifying BLI bright mode (BLI-BRT) and LCI with those obtained via conventional white light imaging (WLI). Interobserver agreement was also assessed.
RESULTS: In experts' evaluation of the images, an improvement in visibility was observed in 73% (60/82) and 20% (16/82) of cases under LCI and BLI-BRT, respectively. In non-experts' evaluation of the images, an improvement in visibility was observed in 76.8% (63/82) and 24.3% (20/82) of cases under LCI and BLI-BRT, respectively. There were no significant differences between experts and non-experts in the evaluation of the images. The improvement in visibility was significantly higher with LCI than with BLI-BRT in experts and non-experts (p < 0.01). With regard to tumor color on WLI, the improvement in the visibility of reddish and whitish tumors was significantly higher than that of isochromatic tumors when LCI was used. The improvement in visibility with LCI was observed in 71% (12/17) and 74% (48/65) of patients with and without Helicobacter pylori (Hp) eradication, respectively; no significant difference in improvement was observed between these groups. The interobserver agreement was good to satisfactory at ≥ 0.62.
CONCLUSIONS: In conclusion, our study showed that LCI improved the visibility of EGC, regardless of the level of endoscopists' experience or Hp eradication in patients, particularly for EGCs with a reddish or whitish color. The improvement in visibility was significantly higher with LCI than that with BLI.

Entities:  

Keywords:  Blue laser imaging; Early gastric cancer; Linked color imaging; Visibility

Mesh:

Year:  2017        PMID: 29216843      PMCID: PMC5721593          DOI: 10.1186/s12876-017-0707-5

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


Background

Gastric cancer is one of the most common cancers, and is also a common cause of cancer-related death. [1] With the development of endoscopic treatments, such as endoscopic submucosal dissection (ESD), patients with early gastric cancer (EGC) can now undergo curative resection with minimal invasiveness, compared with surgery. [2, 3] Therefore, the detection of the cancer at an early stage is very important to obtain good outcomes. However, it is occasionally difficult to achieve an early diagnosis of patients with EGC using conventional white-light imaging (WLI). Superficial EGCs in particular tend to be missed during conventional gastrointestinal endoscopy. Chromoendoscopy with indigo carmine or acetic acid-indigo carmine mixture offers advantages over conventional gastrointestinal endoscopy [4-9]; however, with this technique the procedure is more complex and time-consuming. Various image-enhanced endoscopy (IEE) techniques have been developed to enhance microvascular contrast and facilitate the resolution of minute superficial patterns and color differences, including the image processing from the image illuminated by the short wavelength light such as narrow band imaging (NBI) or blue laser imaging (BLI), and post image processing such as flexible spectral imaging color enhancement (FICE) or i-scan. [10-15] These IEE images are simple and easy to obtain, as the procedure only involves pushing a button, without the need for a dye solution. Fujifilm have developed an endoscopic system, “LASEREO” which quips two lasers as the illumination light source instead of a conventional Xenon lamp. One of them is for the white light illumination by stimulating the phosphor on the tip of the endoscope, and the other one produces short wavelength light for BLI. The BLI light is made from the combination of a strong laser light with a 410 nm wavelength, weak laser light with a 450 nm wavelength, and fluorescent light. The lighting provides three observation modes by changing the intensity of the two lasers: BLI mode, BLI bright mode (BLI-BRT), and white light mode. The BLI-BRT mode is brighter than the BLI mode and is intended to improve the detection of gastrointestinal neoplastic lesions. [15] Recently, linked color imaging (LCI)—a color enhancement feature of the LASEREO system—was developed, which ensures the simultaneous expansion and reduction of color information. By using LCI, a reddish mucosa becomes redder in color, whereas a whitish mucosa becomes whiter in color. Each imaging mode, WLI, BLI, BLI- BRT, LCI, is generated by changing the power balance of these two lasers electronically and the specific digital image processing. Therefore, white light mode, BLI mode, BLI-BRT, and LCI can be easily changed by pushing a button. However, to our knowledge, no detailed reports have been published on the improvement of visibility of EGC using LCI and BLI. If LCI improves the visibility of EGC in this study, the result can provide the bridge between an idea that LCI can be used as a screening tool and the study that reveal the true efficacy of LCI for detecting an EGC in screening endoscopy. In the present study, we aimed to assess the change in visibility of EGC using LCI and BLI compared with WLI.

Patients and Methods

Patients

We enrolled 82 consecutive patients (82 EGCs) who were diagnosed with EGC using LCI and BLI, and who underwent ESD at Hiroshima University Hospital between April 2014 and August 2015. Endoscopic images of the tumor were obtained with WLI, BLI, and LCI. While using BLI, we opted for the BLI-BRT mode to maintain brightness. These images were obtained from the same distance and angle as the non-magnified images.

Setting of endoscopic equipment

The following equipment was used for the study: WLI, BLI, and LCI endoscopes (EG-L590ZW; FUJIFILM Co, Tokyo, Japan), light sources (LASEREO LL-4450; Fujifilm Co), and video processors (AdvanciaHD VP-4450HD; FUJIFILM Co). In the WLI, the structure enhancement function and color mode were set at H + 2 + 4 and C1. BLI and BLI-BRT as delicate as possible in clinical setting level, not complicated engineering. In the BLI-BRT and LCI, the structure enhancement function and color mode were set at the B8 level and level 1.

Imaging technique with the LCI system

In the LCI mode, information of the blood vessels on the mucous surface, the mucosal pattern, and the information acquired by WLI are obtained together by simultaneously irradiating light with a short wavelength (narrow band) and white light in appropriate balance. To easily recognize the differences in colors similar to the mucosal color, the acquired color information is reallocated. Thus, LCI ensures expansion of the color information around the typical mucosal color so that a reddish color appears redder in color, whereas a whitish color appears whiter in color (Fig. 1) However, since LCI keeps the color balance of the blue or green color from conventional white light imaging, the observer doesn’t feel discomfort to the image so much. LCI image can be distinguished the slight color changes on the mucosa such as Helicobacter pylori (Hp)-associated gastritis or intestinal metaplasia those are sometimes difficult to see by the conventional white light imaging [16-18].
Fig. 1

Principle of linked color imaging

Principle of linked color imaging

Methods

Five expert endoscopists, who performed > 5000 esophagogastroduodenoscopies, and 5 non-expert endoscopists, who performed ≤ 5000 esophagogastroduodenoscopies, evaluated the images retrospectively. The endoscopic images were presented to each of the endoscopists in a random order for comparison with the images obtained via WLI. Endoscopists scored each of the images obtained via LCI and BLI-BRT for visibility of the tumors according to the following scale: +2 (improved visibility), +1 (somewhat improved visibility), 0 (visibility equivalent to that of WLI), −1 (somewhat worsened visibility), and −2 (worsened visibility), as previously reported. [12] The 10 endoscopists’ scores for each image were tallied. The maximum possible score for any image was +10 and the minimum possible score was −10. A total score of ≥ +5 indicated that the image had an improved visibility, a score between +4 and −4 indicated equivalent visibility, and a score of ≤ −5 indicated worsened visibility (Fig. 2). We also examined the interobserver agreement in relation to the evaluation of the images obtained via LCI and BLI-BRT between the two groups of endoscopists. The interobserver agreement was calculated at 3 levels: improved (+2), equivalent (−1 to +1), and worsened (−2). The patient and tumor characteristics of this study are shown in Table 1.
Fig. 2

Endoscopic images obtained using linked color imaging (LCI) and blue laser imaging (BLI). A (a) White-light imaging (WLI). (b) LCI. The experts scored this LCI image +8 points, and classified as improved visibility. The non-experts scored this LCI image +9 points, and classified as improved visibility. (c) BLI. The experts scored this BLI image +4 points, and classified as equivalent visibility. The non-experts scored this BLI image +2 points, and classified as equivalent visibility. B (a) White-light imaging (WLI). (b) LCI. The experts scored this LCI image +5 points, and classified as improved visibility. The non-experts scored this LCI image +7 points, and classified as improved visibility. (c) BLI. The experts scored this BLI image −5 points, and classified as worsened visibility. The non-experts scored this BLI image −7 points, and classified as worsened visibility

Table 1

Characteristics of the patients and tumors

FactorsNo. of patients or tumors (n = 82)
Sex ratio (M/F)53/29
Age, years, mean ± SD69.6 ± 11.4
Infection with Hp
 Positive65 (79)
 Negative0 (0)
 Eradicated17 (21)
Tumor size, mm, mean ± SD15.5 ± 11.1
Location of tumor
 Upper25 (30)
 Middle31 (38)
 Lower26 (32)
Color
 Red40 (49)
 Isochromatic20 (24)
 White22 (27)
Macroscopic type
 0-IIa26 (32)
 0-IIc56 (68)
Histological type
 Differentiated72 (88)
 Undifferentiated10 (12)
Depth
 Mucosa74 (95)
 Submucosa8 (5)
(%)

Hp, Helicobacter pylori

Endoscopic images obtained using linked color imaging (LCI) and blue laser imaging (BLI). A (a) White-light imaging (WLI). (b) LCI. The experts scored this LCI image +8 points, and classified as improved visibility. The non-experts scored this LCI image +9 points, and classified as improved visibility. (c) BLI. The experts scored this BLI image +4 points, and classified as equivalent visibility. The non-experts scored this BLI image +2 points, and classified as equivalent visibility. B (a) White-light imaging (WLI). (b) LCI. The experts scored this LCI image +5 points, and classified as improved visibility. The non-experts scored this LCI image +7 points, and classified as improved visibility. (c) BLI. The experts scored this BLI image −5 points, and classified as worsened visibility. The non-experts scored this BLI image −7 points, and classified as worsened visibility Characteristics of the patients and tumors Hp, Helicobacter pylori All patients provided written informed consent to undergo ESD and be enrolled in the study. The study was approved by the institutional review board and the ethics committees of Hiroshima University (No. 156). In addition, this study was performed in accordance with the World Medical Association Helsinki Declaration.

Statistical analysis

Quantitative data are expressed as a mean and standard deviation (SD) or percentages. Rate of improvement between modalities, endoscopists, and clinicopathological features were compared by using the Chi-square test with Yates correction. P < 0.05 was considered statistically significant. The interobserver agreement was measured using the kappa statistic. All statistical analysis was performed using JMP software (SAS International Inc., Cary, NC).

Results

The findings of LCI and BLI-BRT are shown in Table 2. The evaluation of the images by the experts showed that with LCI, improved visibility was observed in 73.1% (60/82) of cases and equivalent visibility was observed in 26.9% (22/82) of cases; none of the cases showed decreased visibility. With BLI-BRT, improved visibility was observed in 19.5% (16/82) of cases, equivalent visibility was observed in 67.0% (55/82) of cases, and worsened visibility was observed in 13.5% (11/82) of cases. The evaluation of the images by the non-experts showed that with LCI, improved visibility was observed in 76.8% (63/82) of cases and equivalent visibility was observed in 23.2% (19/82) of cases; none of the cases showed decreased visibility. With BLI-BRT, improved visibility was observed in 24.3% (20/82) of cases, equivalent visibility was observed in 59.8% (49/82) of cases, and worsened visibility was observed in 15.9% (13/82) of cases. There were no significant differences between experts and non-experts with the evaluation of the images. The improvement in visibility was significantly higher with LCI than that with BLI (p < 0.01), and there were no cases where LCI worsened visibility in experts and non-experts.
Table 2

Evaluation of the visibility of early gastric cancer with LCI and BLI-BRT, compared to that with white light imaging

FactorsExpertNon-expert
LCIBLI-BRTLCIBLI-BRT
Improved73.1% (60/82)a 19.5% (16/82)b 76.8% (63/82)c 24.3% (20/82)d
Unchanged26.8% (22/82)67.0% (55/82)23.2% (19/82)59.8% (49/82)
Worsened0% (0/82)13.4% (11/82)0% (0/82)15.9% (13/82)

LCI linked color imaging, BLI-BRT blue laser imaging bright mode

a vs b: p < 0.01, c vs d: p < 0.01

Evaluation of the visibility of early gastric cancer with LCI and BLI-BRT, compared to that with white light imaging LCI linked color imaging, BLI-BRT blue laser imaging bright mode a vs b: p < 0.01, c vs d: p < 0.01 The rate of improvement in visibility using LCI and BLI-BRT according to each clinicopathological feature in experts’ evaluation of images is shown in Table 3. With regard to tumor color using WLI, the rate of improvement in visibility with LCI was 85% (34/40) for reddish tumors, 45% (10/22) for isochromatic tumors, and 80% (16/20) for whitish tumors. The rate of improvement in visibility with LCI was significantly higher for reddish and whitish tumors than for isochromatic tumors. With regard to Hp infection, the rates of improvement in visibility with LCI were 74% (48/65) and 71% (12/17) in patients without and with Hp eradication, respectively. The improvement in visibility was not significantly different in these groups, regardless of Hp eradication. With BLI-BRT, no significant difference in improvement in visibility was observed according to each clinicopathological feature. We also analyzed which clinicopathological features of the lesion had the worse effect on visibility with BLI-BRT; there were no significant differences (Table 4).
Table 3

Rate of improvement in visibility of early gastric cancer with LCI and BLI-BRT according to the characteristics of early gastric cancer in experts’ evaluation of the images

FactorsRate of improvement in visibility
LCIBLI-BRT
Infection with Hp
 Positive74% (48/65)18% (12/65)
 Negative0% (0/0)0% (0/0)
 Eradicated71% (12/17)24% (4/17)
Tumor size, mm
  < 2070% (40/57)18% (10/57)
  ≥ 2080% (20/25)24% (6/25)
Location of tumor
 Upper76% (19/25)12% (3/25)
 Middle74% (23/31)23% (7/31)
 Lower69% (18/26)23% (6/26)
Color
 Red85% (34/40)a 28% (11/40)
 Isochromatic45% (10/22)b 18% (4/22)
 White80% (16/20)c 5% (1/20)
Macroscopic type
 0-IIa69% (18/26)19% (5/26)
 0-IIc75% (42/56)20% (11/56)
Histological type
 Differentiated71% (51/72)19% (14/72)
 Undifferentiated90% (9/10)20% (2/10)
Depth
 Mucosa74% (55/74)22% (16/74)
 Submucosa63% (5/8)0% (0/8)

LCI linked color imaging, BLI blue laser imaging bright mode, Hp Helicobacter pylori

a vs b, b vs c: p < 0.05

Table 4

Rate of worse in visibility of early gastric cancer with BLI-BRT according to the characteristics of early gastric cancer in experts’ evaluation of the images

FactorsRate of worse in visibility with BLI-BRT
Infection with Hp
 Positive11% (7/65)
 Negative0% (0/0)
 Eradicated24% (4/17)
Tumor size, mm
  < 2016% (9/57)
  ≥ 208% (2/25)
Location of tumor
 Upper16% (4/25)
 Middle13% (4/31)
 Lower12% (3/26)
Color
 Red8% (3/40)
 Isochromatic23% (5/22)
 White15% (3/20)
Macroscopic type
 0-IIa8% (2/26)
 0-IIc16% (9/56)
Histological type
 Differentiated11% (8/72)
 Undifferentiated30% (3/10)
Depth
 Mucosa14% (10/74)
 Submucosa13% (1/8)

LCI linked color imaging, BLI-BRT blue laser imaging bright mode, Hp, Helicobacter pylori

Rate of improvement in visibility of early gastric cancer with LCI and BLI-BRT according to the characteristics of early gastric cancer in experts’ evaluation of the images LCI linked color imaging, BLI blue laser imaging bright mode, Hp Helicobacter pylori a vs b, b vs c: p < 0.05 Rate of worse in visibility of early gastric cancer with BLI-BRT according to the characteristics of early gastric cancer in experts’ evaluation of the images LCI linked color imaging, BLI-BRT blue laser imaging bright mode, Hp, Helicobacter pylori Interobserver agreements for LCI and BLI-BRT were 0.68 and 0.62 and 0.72 and 0.65 for experts and non-experts, respectively. The interobserver agreement was good to satisfactory, and did not significantly differ between LCI and BLI-BRT (Table 5).
Table 5

Interobserver agreements for evaluation of visibility in expert and non-expert

ModalityInterobserver agreement (kappa value)
ExpertNon-expert
LCI0.680.72
BLI-BRT0.620.65

LCI linked color imaging, BLI-BRT blue laser imaging bright mode

Interobserver agreements for evaluation of visibility in expert and non-expert LCI linked color imaging, BLI-BRT blue laser imaging bright mode

Discussion

In this study, the visibility of EGC with non-magnifying BLI was not significantly improved. By using BLI, the color of the tumor and the surrounding mucosa tend to both be dark because BLI is based on a narrow-band observation function. In the esophagus or colon, we can obtain bright endoscopic images by using BLI-BRT. However, the luminal area of the stomach is much larger than that of the esophagus and colon; hence, this study suggested that non-magnifying BLI may not suitable for detection of EGC. On the other hand, LCI improved the visibility of EGC by 70% or more in experts and non-experts. This result suggests that LCI may be useful in screening or surveillance endoscopy to identify EGC. Moreover, there were no significant differences between the experts and non-experts on the evaluation of images, which suggests that LCI improves the visibility of EGC regardless of the level of the endoscopists’ experience. One major difference between LCI and the other IEE methods is the brightness. For instance, NBI is very reliable and commonly used to diagnose EGC via magnification. [10] However, it is difficult to identify EGCs from a distance as the endoscopic images obtained via NBI are relatively dark. Moreover, meta-analyses have indicated that NBI in conjunction with the previous endoscopy system is not effective for detecting colorectal neoplasia, and that a new generation of NBI devices is needed to improve the brightness. [19, 20] In contrast, LCI images are very bright, and hence, the entire stomach can be clearly observed. Fukuda et al. [18] reported that using LCI, they detected two synchronous flat EGCs that were missed by WLI in a patient who was to undergo ESD for another depressed tumor. LCI ensures the simultaneous expansion and reduction of color information, and hence, a reddish color would appear to be redder and a whitish color would appear to be whiter; thus, EGC can be more easily detected. Although the visibility of isochromatic tumors did not markedly improve with LCI, as there is only a minor difference in color between these tumors and the surrounding mucosa, most EGCs are reddish or whitish in color, and would be more visible under LCI. The association between Hp infection and gastric cancer development is well established, based on evidence from both epidemiological [21, 22] and experimental studies. [23, 24] Compared to individuals not infected with Hp, the odds ratio for gastric cancer is more than 20-fold among individuals infected with Hp. [25] A recent prospective study in Japan indicated that the incidence of metachronous gastric cancer is reduced in cases where Hp eradication therapy is provided following the endoscopic resection of EGC. [26] Moreover, several studies have indicated that the visibility of EGC after successful Hp eradication therapy worsens with WLI as the height of the tumors decrease and the tumor surface becomes unclear due to coverage with low-grade atypia. [27-29] In the present study, we assessed the improvement in the visibility of EGC in cases with and without successful Hp eradication therapy. Although no significant difference was observed between these 2 groups, the visibility improvement rate was high even in patients with eradicated Hp infection. This result suggests that LCI could improve the visibility of EGC after successful Hp eradication therapy. The present study is the first detailed report that evaluates the visibility of EGC with LCI and BLI. However, this study has some limitations. First, this study is retrospective in nature, and involved a review of endoscopic images. Hence, it may not reflect real-time prospective detection during surveillance endoscopy, and may have some bias. A prospective study should be performed to investigate the detectability of EGC by dividing patients into two groups such that one group is examined by WLI, while the other group is examined by LCI. Second, the study was conducted only in a single academic center in Japan and may lack the generalizability to other practices worldwide.

Conclusion

In conclusion, our study showed LCI improved the visibility of EGC, regardless of the level of endoscopists’ experience or Hp eradication in patients, particularly for EGCs with a reddish or whitish color. The improvement in visibility was significantly higher with LCI than that with BLI.
  28 in total

1.  Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful Helicobacter pylori eradication therapy.

Authors:  Yoko Kitamura; Masanori Ito; Taiji Matsuo; Tomoyuki Boda; Shiro Oka; Masaharu Yoshihara; Shinji Tanaka; Kazuaki Chayama
Journal:  Helicobacter       Date:  2014-04-28       Impact factor: 5.753

2.  Endoscopic mucosal resection for treatment of early gastric cancer.

Authors:  H Ono; H Kondo; T Gotoda; K Shirao; H Yamaguchi; D Saito; K Hosokawa; T Shimoda; S Yoshida
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese.

Authors:  Taiji Matsuo; Masanori Ito; Shunsuke Takata; Shinji Tanaka; Masaharu Yoshihara; Kazuaki Chayama
Journal:  Helicobacter       Date:  2011-12       Impact factor: 5.753

4.  Improvement in the visibility of colorectal polyps by using blue laser imaging (with video).

Authors:  Naohisa Yoshida; Takashi Hisabe; Ryohei Hirose; Kiyoshi Ogiso; Yutaka Inada; Hideyuki Konishi; Nobuaki Yagi; Yuji Naito; Yoshiaki Aomi; Kazeo Ninomiya; Go Ikezono; Masaaki Terasawa; Kenshi Yao; Toshiyuki Matsui; Akio Yanagisawa; Yoshito Itoh
Journal:  Gastrointest Endosc       Date:  2015-04-04       Impact factor: 9.427

5.  Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up.

Authors:  M Ito; S Tanaka; S Takata; S Oka; S Imagawa; H Ueda; Y Egi; Y Kitadai; W Yasui; M Yoshihara; K Haruma; K Chayama
Journal:  Aliment Pharmacol Ther       Date:  2005-03-01       Impact factor: 8.171

6.  Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study.

Authors:  Yuzo Sakai; Reiko Eto; Junji Kasanuki; Fukuo Kondo; Kazuki Kato; Makoto Arai; Takuto Suzuki; Michiko Kobayashi; Tomoaki Matsumura; Dan Bekku; Kenichi Ito; Shingo Nakamoto; Takeshi Tanaka; Osamu Yokosuka
Journal:  Gastrointest Endosc       Date:  2008-06-17       Impact factor: 9.427

7.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

Authors:  A Nomura; G N Stemmermann; P H Chyou; I Kato; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

8.  Linked color imaging technology facilitates early detection of flat gastric cancers.

Authors:  Hisashi Fukuda; Yoshimasa Miura; Yoshikazu Hayashi; Takahito Takezawa; Yuji Ino; Masahiro Okada; Hiroyuki Osawa; Alan K Lefor; Hironori Yamamoto
Journal:  Clin J Gastroenterol       Date:  2015-11-11

9.  Evaluation and validation of computed virtual chromoendoscopy in early gastric cancer.

Authors:  Ritsuo Mouri; Shigeto Yoshida; Shinji Tanaka; Shiro Oka; Masaharu Yoshihara; Kazuaki Chayama
Journal:  Gastrointest Endosc       Date:  2009-01-18       Impact factor: 9.427

10.  [Endoscopic diagnosis of early gastric cancer].

Authors:  Shiro Oka; Shinji Tanaka; Norifumi Numata; Yoji Sanomura; Kazuaki Chayama
Journal:  Nihon Rinsho       Date:  2012-10
View more
  14 in total

1.  Linked Color Imaging Highlights Flat Early Gastric Cancer.

Authors:  Kimitoshi Kubo; Noriko Kimura; Soichiro Matsuda; Momoko Tsuda; Mototsugu Kato
Journal:  Case Rep Gastroenterol       Date:  2019-12-12

2.  Magnified endoscopy with texture and color enhanced imaging with indigo carmine for superficial nonampullary duodenal tumor: a pilot study.

Authors:  Kenichiro Okimoto; Tomoaki Matsumura; Daisuke Maruoka; Akane Kurosugi; Wataru Shiratori; Ariki Nagashima; Tsubasa Ishikawa; Tatsuya Kaneko; Kengo Kanayama; Naoki Akizue; Yuki Ohta; Takashi Taida; Keiko Saito; Jun Kato; Naoya Kato
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

3.  Ability of blue laser imaging with magnifying endoscopy for the diagnosis of gastric intestinal metaplasia.

Authors:  Honglei Chen; Yanan Liu; Yi Lu; Xutao Lin; Qiuning Wu; Jiacheng Sun; Chujun Li
Journal:  Lasers Med Sci       Date:  2018-05-18       Impact factor: 3.161

4.  Linked color imaging can enhance recognition of early gastric cancer by high color contrast to surrounding gastric intestinal metaplasia.

Authors:  Hisashi Fukuda; Yoshimasa Miura; Hiroyuki Osawa; Takahito Takezawa; Yuji Ino; Masahiro Okada; Tsevelnorov Khurelbaatar; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  J Gastroenterol       Date:  2018-10-05       Impact factor: 7.527

5.  Clinical Usefulness of Dual Red Imaging in Gastric Endoscopic Submucosal Dissection: A Pilot Study.

Authors:  Naoki Yorita; Shiro Oka; Shinji Tanaka; Takahiro Kotachi; Naoko Nagasaki; Kosaku Hata; Kazutaka Kuroki; Kazuhiko Masuda; Mio Kurihara; Mariko Kiso; Tomoyuki Boda; Masanori Ito; Kazuaki Chayama
Journal:  Clin Endosc       Date:  2019-09-03

6.  RGB Pixel Brightness Characteristics of Linked Color Imaging in Early Gastric Cancer: A Pilot Study.

Authors:  Xue Sun; Li Zhao
Journal:  Gastroenterol Res Pract       Date:  2020-03-31       Impact factor: 2.260

Review 7.  Linked color imaging for the detection of early gastrointestinal neoplasms.

Authors:  Satoshi Shinozaki; Hiroyuki Osawa; Yoshikazu Hayashi; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Therap Adv Gastroenterol       Date:  2019-11-01       Impact factor: 4.409

8.  Linked color imaging improves the endoscopic visibility of gastric mucosal cancers.

Authors:  Yoshiyasu Kitagawa; Takuto Suzuki; Taro Hara; Rino Nankinzan; Hideyuki Takashiro; Osamu Sugita; Hiroshi Imazeki; Taketo Yamaguchi
Journal:  Endosc Int Open       Date:  2019-01-18

9.  Recent advances in diagnostic upper endoscopy.

Authors:  Jun-Liang Teh; Asim Shabbir; Soon Yuen; Jimmy Bok-Yan So
Journal:  World J Gastroenterol       Date:  2020-01-28       Impact factor: 5.742

10.  Application of linked color imaging in the diagnosis of early gastrointestinal neoplasms and precancerous lesions: a review.

Authors:  Shanshan Wang; Lei Shen; Hesheng Luo
Journal:  Therap Adv Gastroenterol       Date:  2021-07-06       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.